Mark Andrew White - Feb 16, 2024 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Role
Chief Medical Officer
Signature
/s/ Martin Wilson, as attorney-in-fact for Mark Andrew White
Stock symbol
RCKT
Transactions as of
Feb 16, 2024
Transactions value $
$0
Form type
4
Date filed
2/21/2024, 08:54 PM
Previous filing
Apr 12, 2023
Next filing
Apr 10, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCKT Common Stock Award $0 +11.1K +14.47% $0.00 87.8K Feb 16, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RCKT Stock Option (Right to Buy) Award $0 +32.7K $0.00 32.7K Feb 16, 2024 Common Stock 32.7K $30.01 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Holdings are Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on February 16, 2025, with the remaining shares vesting in equal quarterly installments over the following two years.
F2 This option represents a right to purchase a total of 32,727 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 16, 2025, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.